Antonio A.
- Country
- Italy
- Department
- Oncology
Research Overview
- A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)
- Sotorasib and Combination Therapy Versus Standard Chemotherapy in Treatment-Naïve Patients with KRAS p.G12C-Mutated Metastatic Colorectal Cancer
- Pumitamig and Combination Therapy Versus Bevacizumab and Combination Therapy in Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Data & Insights
Has run more than one trial at 259 of 480 partner sites.
Specializations
Gastrointestinal Oncology
The investigator specializes in treating advanced colorectal cancer, with particular focus on RAS/BRAF wild-type metastatic variants and microsatellite instability-high (MSI-H) cases.
- Targeted Therapy Development
- Immunotherapy Integration
- Biomarker-Driven Treatment Strategies
Hepatobiliary Cancer Research
Expertise in treating advanced hepatocellular carcinoma and biliary tract cancers, implementing novel therapeutic approaches combining immunomodulators with targeted agents.
- Novel Immunotherapy Combinations
- First-line Treatment Strategies
- Recurrence Prevention Protocols
Upper GI Malignancies
Focus on esophageal carcinoma and gastroesophageal cancer, particularly in developing treatment protocols incorporating HER2-targeted therapies and chemoradiotherapy approaches.
- Multimodal Treatment Approaches
- Molecular-Based Therapies
- Minimal Residual Disease Management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.